Sponsor

ROXALL Medizin GmbH

Germany Carl-Petersen-Strasse 4, Hamm-Nord, 20535 Hamburg, Germany

About the sponsor

ROXALL Medizin GmbH focuses on moderate-to-severe allergic rhinitis and rhinoconjunctivitis linked to airborne allergens, with trials centered on symptom control and treatment tolerability in patients affected by seasonal and perennial disease patterns.

House dust mite allergy
Birch pollen allergy
Grass pollen allergy
Olive pollen allergy

The research portfolio includes both subcutaneous immunotherapy and sublingual immunotherapy approaches for upper-airway allergic disease.

About Specializations

ROXALL Medizin GmbH runs clinical trials in conditions such as Conjunctivitis allergic, Seasonal allergy, Rhinitis allergic, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Quick filters

10 clinical trials

Conjunctivitis allergic+1

Not yet recruiting

Diagnostic Accuracy of Parietaria judaica Pollen Extract (SPT‑RX) in a Skin Prick Test Drug Combination for Adults with Allergic Rhinitis and Controlled Mild Asthma

InvestigationalNo placebo

Diagnostic Accuracy of Parietaria judaica Pollen Extract (SPT‑RX) in a Skin Prick Test Drug Combination for Adults with Allergic Rhinitis and Controlled Mild Asthma

InvestigationalNo placebo

Germany

Participants:18–64 years
Substances:Phleum Pratense Pollen Extract
Sponsor:ROXALL Medizin GmbH

Contact Research Centre

Conjunctivitis allergic+1

Not recruiting

Testing sublingual immunotherapy with dermatophagoides pteronyssinus extract for adults with moderate to severe house dust mite allergy

Investigational

Testing sublingual immunotherapy with dermatophagoides pteronyssinus extract for adults with moderate to severe house dust mite allergy

Investigational

Germany

Participants:18–64 years
Sponsor:ROXALL Medizin GmbH

Contact Research Centre

Conjunctivitis allergic+1

Not recruiting

Study of sublingual immunotherapy with Phleum pratense pollen extract spray in patients with moderate to severe grass pollen allergic rhinitis

Investigational

Study of sublingual immunotherapy with Phleum pratense pollen extract spray in patients with moderate to severe grass pollen allergic rhinitis

Investigational

Germany

Participants:18–64 years
Substances:Phleum Pratense Pollen Extract
Sponsor:ROXALL Medizin GmbH

Contact Research Centre

Conjunctivitis allergic+1

Not recruiting

Study of CLU-RX-PHL injection therapy for patients with moderate to severe grass pollen allergy to find the most effective and safe dose

Investigational

Study of CLU-RX-PHL injection therapy for patients with moderate to severe grass pollen allergy to find the most effective and safe dose

Investigational

Germany

Participants:18–64 years
Sponsor:ROXALL Medizin GmbH

Contact Research Centre

Conjunctivitis allergic+1

Not recruiting

Study of sublingual birch pollen extract (SLI-RX-BET) in different doses for patients with moderate to severe allergic rhinitis caused by birch pollen

Investigational